ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2011 Financial Results
July 28 2011 - 5:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted anticancer products using its antibody expertise
and Targeted Antibody Payload (TAP) technology, today announced
that the Company will host a conference call at 4:30 p.m. ET on
Wednesday, August 3, 2011, to discuss ImmunoGen's financial results
for the three-month period and fiscal year ended June 30, 2011.
Management also will provide an update on the Company and guidance
for ImmunoGen’s fiscal year ending June 30, 2012.
To access the live call by phone, dial 913-312-0648. Passcode:
5587356. The call also may be accessed through the Investor
Information section of the Company's website,
http://www.immunogen.com. Following the live webcast, a replay of
the call will be available at the same location through August 17,
2011.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies,
potent cancer-cell killing agents and engineered linkers. The
Company's TAP technology uses monoclonal antibodies to deliver one
of ImmunoGen's proprietary cancer-cell killing agents specifically
to tumor cells. There are now numerous TAP compounds in clinical
development and a wealth of clinical data reported. ImmunoGen’s
collaborative partners include Amgen, Bayer HealthCare
Pharmaceuticals, Biotest, Novartis, Roche and Sanofi. The most
advanced compound using ImmunoGen's TAP technology, trastuzumab
emtansine (T-DM1), is in Phase III testing through the Company's
collaboration with Genentech, a member of the Roche Group. More
information about ImmunoGen can be found at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
